Drug Profile
Duligotuzumab - Genentech
Alternative Names: Anti-HER3/EGFR DAF; MEHD-7945A; RG 7597; RO-5541078Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Genentech; Roche
- Developer Genentech
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Epidermal growth factor receptor antagonists; ERBB-3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
- Discontinued Colorectal cancer; Head and neck cancer
Most Recent Events
- 04 Jun 2018 Genentech terminates a phase I trial for Solid tumours (Combination therapy, Late stage disease, Metastatic disease) in USA and Spain (NCT01986166)
- 23 Apr 2018 Genentech completes a phase I trial for Solid tumours in USA and Spain (NCT01207323)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in Spain (IV, Infusion)